---
document_datetime: 2024-07-02 14:48:26
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lenalidomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lenalidomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.4149559
conversion_datetime: 2025-12-28 08:40:19.497328
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lenalidomide Accord

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0025/G            | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 26/06/2024                          |                                             | SmPC, Annex II and PL            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                        |                                                                                                                                                                                                                                                                                  |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024            | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                | 02/04/2024 | n/a        |                        |                                                                                                                                                                                                                                                                                  |
| PSUSA/1838/ 202212 | Periodic Safety Update EU Single assessment - lenalidomide                                                                                                                                                                                                                                                                | 31/08/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                |
| R/0021             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                   | 22/06/2023 | 09/08/2023 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lenalidomide Accord in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity |
| IB/0023/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH           | 16/05/2023 | 23/06/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0020/G | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other | 30/11/2022 | n/a |

<div style=\"page-break-after: always\"></div>

| IAIN/0019          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                | 01/06/2022   | n/a        |                 |                                                                                                                                           |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0018            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                     | 07/01/2022   | 30/01/2023 | Annex II and PL |                                                                                                                                           |
| IA/0017            | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                        | 23/09/2021   | n/a        |                 |                                                                                                                                           |
| PSUSA/1838/ 202012 | Periodic Safety Update EU Single assessment - lenalidomide                                                                                                                                        | 22/07/2021   | 16/09/2021 |                 | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1838/202012. |
| IB/0016            | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                        | 03/08/2021   | n/a        |                 |                                                                                                                                           |
| IB/0015            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                     | 10/05/2021   | n/a        |                 |                                                                                                                                           |
| IA/0014            | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                      | 09/04/2021   | n/a        |                 |                                                                                                                                           |
| IB/0011/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference | 17/02/2021   | 09/03/2021 | SmPC and PL     |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                        |            |            |                        | product -   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------|
| IB/0012/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within range of the currently approved pack sizes | 16/02/2021 | 09/03/2021 | SmPC, Labelling and PL | the         |
| IB/0010/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                                                                                                                                                                                 | 18/12/2020 | 29/01/2021 | SmPC, Annex II and PL  |             |

<div style=\"page-break-after: always\"></div>

|                    | the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                         |            |            |                 |                                                                                                                                           |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1838/ 201912 | Periodic Safety Update EU Single assessment - lenalidomide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/07/2020 | 24/09/2020 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1838/201912. |
| IB/0008/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 09/09/2020 | 22/10/2020 | SmPC and PL     |                                                                                                                                           |
| IAIN/0009          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                       | 28/07/2020 | 22/10/2020 | Annex II and PL |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IB/0004            | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                         | 13/03/2020   | n/a        |                        |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IB/0005            | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                              | 20/02/2020   | 27/03/2020 | SmPC                   |                                   |
| PSUSA/1838/ 201812 | Periodic Safety Update EU Single assessment - lenalidomide                                                                                                                                                                             | 05/09/2019   | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0002          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 08/03/2019   | 27/03/2020 | Annex II and PL        |                                   |
| T/0001             | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 11/01/2019   | 01/03/2019 | SmPC, Labelling and PL |                                   |